Preferred Label : CDK4/6 Inhibitor CS3002;
NCIt definition : An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types
4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration,
CDK4/6 inhibitor CS3002 selectively targets and inhibits CDK4 and CDK6, which inhibits
the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents
CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses
DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine
kinases that are upregulated in many tumor cell types and play a key role in the regulation
of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.;
Molecule name : CS 3002; CS-3002;
NCI Metathesaurus CUI : CL1411938;
Origin ID : C174417;
UMLS CUI : C5418090;
Semantic type(s)
- concept_is_in_subset
- has_target
